Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.

OBJECTIVE: To describe a patient with neuromyelitis optica (NMO) whose aquaporin 4 (AQP4) antibody levels increased following treatment with interferon beta. DESIGN: Prospective clinical and laboratory case report. SETTING: Institutional referral center for multiple sclerosis (MS). Patient One pati...

Bibliografske podrobnosti
Main Authors:	Palace, J, Leite, M, Nairne, A, Vincent, A
Format:	Journal article
Jezik:	English
Izdano:	2010

Podobne knjige/članki

Antibodies to aquaporin-1 are not present in neuromyelitis optica
od: Waters, P, et al.
Izdano: (2015)

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
od: Paul, F, et al.
Izdano: (2007)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
od: Waters, P, et al.
Izdano: (2016)

NEUROMYELITIS OPTICA SPECTRUM AND RELATIONSHIP WITH AQUAPORIN-4 ANTIBODY DISEASE: THE OXFORD COHORT
od: Leite, M, et al.
Izdano: (2009)

METHOTREXATE MAY BE AN ALTERNATIVE TO AZATHIOPRINE IN NEUROMYELITIS OPTICA WITH AQUAPORIN-4 ANTIBODIES
od: Kitley, J, et al.
Izdano: (2012)

Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis.
od: Waters, P, et al.
Izdano: (2008)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
od: Kitley, J, et al.
Izdano: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
od: Kitley, J, et al.
Izdano: (2013)

Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.
od: Jarius, S, et al.
Izdano: (2008)

Aquaporin-4 Antibody Isoform Binding Specificity Does Not Explain Clinical Variations in Neuromyelitis Optica
od: Kitley, J, et al.
Izdano: (2013)

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
od: Jarius, S, et al.
Izdano: (2008)

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
od: Jarius, S, et al.
Izdano: (2008)

Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4.
od: Jarius, S, et al.
Izdano: (2008)

Seasonal pattern of variation in neuromyelitis optica relapses
od: Elsone, L, et al.
Izdano: (2012)

Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply.
od: Kitley, J, et al.
Izdano: (2014)

Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays.
od: Waters, P, et al.
Izdano: (2008)

Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients.
od: Akman-Demir, G, et al.
Izdano: (2011)

Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative Study
od: Kitley, J, et al.
Izdano: (2014)

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
od: Kitley, J, et al.
Izdano: (2014)

Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica
od: Wilson, R, et al.
Izdano: (2018)

Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders
od: Kitley, J, et al.
Izdano: (2013)

A practical guide to the treatment of neuromyelitis optica.
od: Palace, J, et al.
Izdano: (2012)

Neuromyelitis optica in patients with increased interferon alpha concentrations
od: Williams, J, et al.
Izdano: (2019)

Novel Anti-Neuronal Antibodies in Neuromyelitis Optica Patients with or without Aquaporin-4 Antibodies
od: Cavus, F, et al.
Izdano: (2013)

Good response to Ofatumumab in a child with severe relapsing Neuromyelitis Optica
od: Sedani, S, et al.
Izdano: (2012)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
od: Elsone, L, et al.
Izdano: (2012)

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
od: Tackley, G, et al.
Izdano: (2016)

Anti-aquaporin 4 antibody-positivity of Korean patients with neuromyelitis optica spectrum disorders
od: Min, J, et al.
Izdano: (2010)

Risk factors for immunosuppression-associated infections in aquaporin-4 antibody mediated neuromyelitis optica spectrum disorders
od: Cheng, F, et al.
Izdano: (2014)

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
od: Nour, M, et al.
Izdano: (2015)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
od: Pittock, S, et al.
Izdano: (2019)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.
od: Kitley, J, et al.
Izdano: (2014)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
od: Kitley, J, et al.
Izdano: (2014)

Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
od: Kim, S, et al.
Izdano: (2013)

Distinction of aquaporin-4 antibody positive neuromyelitis optica from multiple sclerosis using diffusion tensor and myelin water imaging
od: Matthews, L, et al.
Izdano: (2011)

Use of mitoxantrone in neuromyelitis optica.
od: Kitley, J, et al.
Izdano: (2011)

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
od: Kitley, J, et al.
Izdano: (2012)

Sequential voltage-gated potassium channel and aquaporin-4 antibodies in a patient with seropositive myasthenia gravis, limbic encephalitis and neuromyelitis optica
od: Jacobson, L, et al.
Izdano: (2008)

Treatment of Neuromyelitis Optica: Review and Recommendations.
od: Kimbrough, D, et al.
Izdano: (2012)

Treatment of neuromyelitis optica: Review and recommendations
od: Kimbrough, D, et al.
Izdano: (2012)